Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Characterization of opioid use in sickle cell disease
source: Pharmacoepidemiology and Drug Safety journal
authors: Han J, Zhou J, Saraf SL, Gordeuk VR, Calip GSsummary/abstract:
Opioid analgesics are commonly used to treat vaso-occlusive pain episodes in sickle cell disease (SCD), but comprehensive evidence characterizing opioid use in this patient population is limited. Our objective was to characterize opioid use patterns among SCD patients using a large nationwide database.
A large, US medical claims database was utilized to identify a cohort of 3882 SCD patients, and characteristics of opioid use were analyzed. Clinical variables including age, gender, medication use, health care utilization, and medical history were evaluated for correlations with opioid use.
Forty percent of patients took opioid medications during a 12-month span, and the prevalence of any opioid use was highest for 20 to 29-year-old patients (58%). The median daily opioid dose was 1.85 mg (interquartile range: 0.62-10.68 mg) oral morphine equivalents (OME). While most opioid users took between 0 and 5 mg OME daily, 3% of pediatric patients and 23% of adult patients used more than 30-mg OME daily. High-dose opioid use was associated with older age, hydroxyurea therapy, nonsteroidal anti-inflammatory drug (NSAID) use, and frequent inpatient hospitalizations. In multivariable-adjusted analyses, patients with vaso-occlusive complications such as pain crisis (OR = 3.8, 95% CI 2.7-5.3) and avascular necrosis (AVN) (OR = 3.7, 95% CI 2.7-5.1) were associated with high-dose opioid use.
Our study showed that only 40% SCD patients were on opioid analgesics during a 12-month span. However, a non-trivial number of patients used a much higher dose of opioids despite a relatively low average daily opioid dose among SCD patients, particularly with vaso-occlusive complications.
read more full text
Today’s Faces of Sickle Cell Disease: Tosin OlaDuring a long hospitalization in 2005, T...
Santosh L. Saraf, MDDr. Santosh Saraf is an assistant profes...
Sickle Cell Disease in the Emergency Department: Confronting Barriers to Care“You’re too pretty to have a disease...
Successful utilization of an electronic pain diary in a multinational phase 3 interventional study in pediatric sick...Background: Patients with sickle cell a...
SCD Patients Receiving Hydroxyurea in the U.S. Still Face Many ChallengesPeople with sickle cell disease (SCD) tr...
Today’s Faces of Sickle Cell Disease: Linda Thomas WadeLinda Thomas is a health care educator, ...
Robert Molokie, MDDr. Robert Molokie is a hematologist and...
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.